Nat Rev Endocrinol. 2013 Jul;9(7):384-5. doi: 10.1038/nrendo.2013.103. Epub 2013 Jun 4.
Moran et al report two trials of antagonism of the pro-inflammatory cytokine, IL-1, assessing the monoclonal antibody canakinumab and the IL-1 antagonist, anakinra in new-onset Type 1 Diabetes (T1D). The studies both showed that, although relatively safe, there was no efficacy in terms of halting decline in beta cell function. Is this the end of the line for targeting IL-1 in T1D?
莫兰等人报告了两项拮抗促炎细胞因子白细胞介素-1 (IL-1) 的试验，评估了单克隆抗体卡那单抗和白细胞介素-1 拮抗剂阿那白滞素在新发 1 型糖尿病 (T1D) 中的作用。这两项研究都表明，尽管相对安全，但在阻止β细胞功能下降方面没有疗效。这是否意味着针对 T1D 的白细胞介素-1 治疗的终点已经到来？
